Cargando…
Perspectives on statistical strategies for the regulatory biomarker qualification process
Qualification of a biomarker for use in a medical product development program requires a statistical strategy that aligns available evidence with the proposed context of use (COU), identifies any data gaps to be filled and plans any additional research required to support the qualification. Accumula...
Autores principales: | Hendrix, Suzanne B, Mogg, Robin, Wang, Sue Jane, Chakravarty, Aloka, Romero, Klaus, Dickson, Samuel P, Sauer, John-Michael, McShane, Lisa M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293027/ https://www.ncbi.nlm.nih.gov/pubmed/34037457 http://dx.doi.org/10.2217/bmm-2020-0523 |
Ejemplares similares
-
Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson’s Patients Using Digital Mobility Outcomes
por: Viceconti, Marco, et al.
Publicado: (2020) -
Biomarker Qualification at the European Medicines Agency: A Look Under the Hood
por: Berman, Steven, et al.
Publicado: (2022) -
In Pursuit of Greater Reproducibility and Credibility of Early Clinical Biomarker Research
por: McShane, LM
Publicado: (2017) -
Regulatory Aspects in Using Surrogate Markers in Clinical Trials
por: Chakravarty, Aloka
Publicado: (2005) -
Biomarkers in Medicines Development—From Discovery to Regulatory Qualification and Beyond
por: Hendrikse, Natalie M., et al.
Publicado: (2022)